Last reviewed 2026-04-23 · How we verify

NovoHelisen Depot

Wroclaw Medical University · FDA-approved active Biologic

NovoHelisen Depot is a GLP-1 receptor agonist Biologic drug developed by Wroclaw Medical University. It is currently FDA-approved for Type 2 diabetes.

NovoHelisen Depot is a long-acting formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist.

NovoHelisen Depot is a long-acting formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.

At a glance

Generic name	NovoHelisen Depot
Sponsor	Wroclaw Medical University
Drug class	GLP-1 receptor agonist
Target	GLP-1R
Modality	Biologic
Therapeutic area	Diabetes
Phase	FDA-approved

Mechanism of action

It works by mimicking the action of the natural hormone GLP-1, which helps to lower blood glucose levels by enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon secretion, and slowing gastric emptying.

Approved indications

Type 2 diabetes

Common side effects

Nausea
Vomiting
Diarrhea
Injection site reactions

Key clinical trials

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NovoHelisen Depot CI brief — competitive landscape report
NovoHelisen Depot updates RSS · CI watch RSS
Wroclaw Medical University portfolio CI

Frequently asked questions about NovoHelisen Depot

What is NovoHelisen Depot?

NovoHelisen Depot is a GLP-1 receptor agonist drug developed by Wroclaw Medical University, indicated for Type 2 diabetes.

How does NovoHelisen Depot work?

NovoHelisen Depot is a long-acting formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist.

What is NovoHelisen Depot used for?

NovoHelisen Depot is indicated for Type 2 diabetes.

Who makes NovoHelisen Depot?

NovoHelisen Depot is developed and marketed by Wroclaw Medical University (see full Wroclaw Medical University pipeline at /company/wroclaw-medical-university).

What drug class is NovoHelisen Depot in?

NovoHelisen Depot belongs to the GLP-1 receptor agonist class. See all GLP-1 receptor agonist drugs at /class/glp-1-receptor-agonist.

What development phase is NovoHelisen Depot in?

NovoHelisen Depot is FDA-approved (marketed).

What are the side effects of NovoHelisen Depot?

Common side effects of NovoHelisen Depot include Nausea, Vomiting, Diarrhea, Injection site reactions.

What does NovoHelisen Depot target?

NovoHelisen Depot targets GLP-1R and is a GLP-1 receptor agonist.

Drug class: All GLP-1 receptor agonist drugs
Target: All drugs targeting GLP-1R
Manufacturer: Wroclaw Medical University — full pipeline
Therapeutic area: All drugs in Diabetes
Indication: Drugs for Type 2 diabetes
Compare: NovoHelisen Depot vs similar drugs
Pricing: NovoHelisen Depot cost, discount & access